, September 4, 2014 – KineMed, Inc. (www.kinemed.com
) today announced that
the company has received a notice of allowance from the U.S. Patent and Trademark Office for
the invention entitled: “Compositions and Methods of Treatment Using Modulators of
Motoneuron Disease.” The patent allowance covers the treatment of amyotrophic lateral
sclerosis (ALS), or Lou Gehrig’s disease, Parkinson’s disease, and diabetic neuropathy using the
microtubule target modulating agent, noscapine, alone or in combination with a variety of other
Based on KineMed’s research, the Company has shown that noscapine has the ability to normalize
the disruption of microtubule turnover and neuronal transport of cargo proteins which
characterize several neurodegenerative diseases, including ALS and Parkinson’s disease. KineMed
has developed the first in vivo technique for accurately measuring these components of neuronal
dysfunction in humans and experimental animals. “Patent protection of noscapine for use in ALS
and Parkinson’s disease is critical for our plan to advance and de‐risk this drug candidate. Our
ability to identify precisely that a drug is hitting its pathophysiological target and to track its
disease‐modifying effect is unique in these serious neurodegenerative disorders. These
proprietary diagnostic tools will also aid the development of other ALS drugs,” said David
Fineman, KineMed Chairman and CEO.
About KineMed, Inc.
KineMed is a life sciences company that has developed a platform technology with broad
applications in drug development and medical diagnosis. Using its patented technology, KineMed
has developed analytic biomarker tests that measure, in a single sample, the rate of change of
critical biological pathways. KineMed has the unique ability to measure the production and
destruction of key molecules involved in health and disease‐modifying biological processes to
provide meaningful, and previously unavailable, information to transform healthcare decisions.
For more information about KineMed, please visit: www.kinemed.com
Patrick Doyle, Ph.D.
Chief Business Officer
Tel: 510‐655‐6525 ext. 172